Physician profile
Prashant Kolar
NPI 1114175312
$769.27
in general payments reported to CMS, 2019-2025
12 companies · $91.57 in 2025
The $91.57 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.08 · 2021: $103 · 2022: $203 · 2023: $128 · 2024: $182 · 2025: $91.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.77 | 2022-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $133.24 | 2019-2023 | Jynarque |
| Amgen INC. | $66.20 | 2024-2025 | Krystexxa |
| Glaxosmithkline, LLC. | $63.41 | 2021-2023 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.31 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2023-2025 | |
| Horizon Therapeutics Plc | $28.99 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $28.60 | 2023 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.51 | 2025 | Jynarque |
| Boston Scientific Corporation | $24.51 | 2024 | |
| Strongbridge US INC. | $16.15 | 2019 | |
| Abbott Laboratories | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Kolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.